S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ACOR

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

$13.21
+1.30 (+10.91%)
(As of 03/28/2024 ET)
Today's Range
$11.82
$13.32
50-Day Range
$11.91
$17.50
52-Week Range
$8.98
$24.20
Volume
4,531 shs
Average Volume
3,814 shs
Market Capitalization
$16.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ACOR stock logo

About Acorda Therapeutics Stock (NASDAQ:ACOR)

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

ACOR Stock Price History

ACOR Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update
3 Biotech Stocks to Watch in March for Success
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Acorda: No policy vs. TikTok use in PNP
3 Biotech Stocks to Keep an Eye on in 2024
Acorda eyes Pinoy apps vs cybercrimes
Acorda Therapeutics Inc ACOR
3 Biotech Stocks Flashing Year-End 'Buy' Signals"
3 Safe Biotech Stocks to Buy This Week
See More Headlines
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Confirmed)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ACOR
CUSIP
00484M10
Employees
111
Year Founded
1995

Profitability

Net Income
$-65,920,000.00
Pretax Margin
-16.72%

Debt

Sales & Book Value

Annual Sales
$118.57 million
Book Value
$77.13 per share

Miscellaneous

Free Float
1,210,000
Market Cap
$14.77 million
Optionable
No Data
Beta
1.41

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Ron Cohen M.D. (Age 68)
    Founder, CEO, President & Director
    Comp: $984.15k
  • Mr. Michael A. Gesser M.B.A. (Age 61)
    Chief Financial Officer
    Comp: $459.15k
  • Mr. Kerry M. Clem (Age 54)
    Chief Commercial Officer
    Comp: $592.23k
  • Mr. Robert Morales (Age 56)
    Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller
  • Ms. Felicia Vonella
    Vice President of Investor Relations
  • Mr. Neil S. Belloff Esq. (Age 64)
    General Counsel & Corporate Secretary
  • Ms. Tierney Saccavino
    Executive Vice President of Corporate Communications
  • Ms. Denise J. Duca
    Executive Vice President of Human Resources
  • Mr. Andrew Mayer J.D.
    Senior Vice President
  • Sofia Ali
    Senior VP of Operations & Strategic Planning

ACOR Stock Analysis - Frequently Asked Questions

How have ACOR shares performed in 2024?

Acorda Therapeutics' stock was trading at $15.09 at the beginning of 2024. Since then, ACOR stock has decreased by 12.5% and is now trading at $13.21.
View the best growth stocks for 2024 here
.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 9,500 shares, a drop of 14.4% from the February 29th total of 11,100 shares. Based on an average daily volume of 3,800 shares, the short-interest ratio is currently 2.5 days. Approximately 0.8% of the company's shares are sold short.
View Acorda Therapeutics' Short Interest
.

When is Acorda Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our ACOR earnings forecast
.

How can I listen to Acorda Therapeutics' earnings call?

Acorda Therapeutics will be holding an earnings conference call on Monday, April 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "732092".

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) EPS for the quarter, beating analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to the consensus estimate of $30.57 million. Acorda Therapeutics had a negative net margin of 14.35% and a negative trailing twelve-month return on equity of 21.45%.

When did Acorda Therapeutics' stock split?

Acorda Therapeutics shares reverse split on the morning of Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACOR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners